A look at OpenAI-backed Red Queen Bio, an AI biosecurity startup with $36M raised to design antibody drugs against pathogens, including AI-enabled bioweapons (Georgia Wells/Wall Street Journal)

Red Queen Bio, backed by OpenAI, has raised $36 million to develop antibody drugs that target a broad range of pathogens, including those engineered with artificial intelligence. The company uses machine-learning models to predict antibody–antigen interactions and accelerate lead discovery. Its platform aims to provide rapid, scalable countermeasures against emerging biological threats.